MSB 3.21% $1.13 mesoblast limited

Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-155

  1. 155 Posts.
    lightbulb Created with Sketch. 7
    That’s why I sold.

    The analyst that worked in analysts has raised flag before MSB will need to raise funding.

    with this announcement, it solidify the analyst position.
    they will need to do more trials to convince FDA.

    this going to cost $$

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.